Effect of Alemtuzumab vs. Interferon beta-1a on Brain Atrophy in Patients with Early, Active Relapsing-Remitting Multiple Sclerosis

被引：0
|
作者：
Zivadinov, Robert
Dwyer, Michael
Bergsland, Niels
Hussein, Sara
Durfee, Jackie
Ramasamy, Deepa
Cherneva, Mariya
Willis, Laura
Cox, Jennifer
Kennedy, Cheryl
Margolin, David
Rizzo, Marco
Palmer, Jeffrey
机构：
来源：
NEUROLOGY | 2011年 / 76卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：A388 / A388
页数：1
相关论文
共 50 条
  • [1] Interferon beta-1a in relapsing-remitting multiple sclerosis
    Blumhardt, L
    HOSPITAL MEDICINE, 1999, 60 (03): : 192 - 195
  • [2] Effect of Intramuscular Interferon beta-1a on Gray Matter Atrophy in Relapsing-Remitting Multiple Sclerosis
    Nakamura, Kunio
    Rudick, Richard
    Lee, Jar-Chi
    Foulds, Pamela
    Fisher, Elizabeth
    NEUROLOGY, 2010, 74 (09) : A407 - A407
  • [3] Effect of interferon beta-1a on grey matter atrophy progression in relapsing-remitting multiple sclerosis
    Zivadinov, R
    Locatelli, L
    Srinivasaraghavan, B
    Ukmar, M
    Bratina, A
    Maggiore, C
    Bosco, A
    Grop, A
    Pozzi-Mucelli, R
    Catalan, M
    Zorzon, M
    MULTIPLE SCLEROSIS, 2005, 11 (01): : 115 - 115
  • [4] Alemtuzumab vs. Interferon beta-1a in early multiple sclerosis
    Coles, Alasdair J.
    Compston, D. Alastair S.
    Selmaj, Krzysztof W.
    Lake, Stephen L.
    Moran, Susan
    Margolin, David H.
    Norris, Kim
    Tandon, P. K.
    NEW ENGLAND JOURNAL OF MEDICINE, 2008, 359 (17): : 1786 - 1801
  • [5] Rationale for early treatment with interferon beta-1a in relapsing-remitting multiple sclerosis
    Munschauer, FE
    Stuart, WH
    CLINICAL THERAPEUTICS, 1997, 19 (05) : 868 - 882
  • [6] Cost-effectiveness of alemtuzumab vs subcutaneous interferon beta-1a for treatment of active relapsing-remitting multiple sclerosis: payer perspective
    Celestin, C.
    Cutter, G. R.
    Coles, A. J.
    Reimers, A.
    Margolin, D. H.
    MULTIPLE SCLEROSIS JOURNAL, 2014, 20 : 72 - 72
  • [7] Response to treatment with Interferon beta-1a in patients with relapsing-remitting multiple sclerosis
    Vazquez Gomez, Lazaro Aurelio
    Hidalgo Mesa, Carlos
    Broche Perez, Yunier
    Valdes Morales, Yanet
    MEDISUR-REVISTA DE CIENCIAS MEDICAS DE CIENFUEGOS, 2022, 20 (05): : 825 - 833
  • [8] Alemtuzumab improves quality-of-life outcomes compared with subcutaneous interferon beta-1a in patients with active relapsing-remitting multiple sclerosis
    Arroyo Gonzalez, Rafael
    Kita, Mariko
    Crayton, Heidi
    Havrdova, Eva
    Margolin, David H.
    Lake, Stephen L.
    Giovannoni, Gavin
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 (10) : 1367 - 1376
  • [9] Alemtuzumab decreases new lesion formation and slows the rate of brain atrophy in relapsing-remitting Multiple sclerosis patients previously treated with subcutaneous interferon beta-1a
    Barkhof, F.
    Rovira, A.
    Ziemssen, T.
    Margolin, D. H.
    Kasten, L.
    Arnold, D. L.
    EUROPEAN JOURNAL OF NEUROLOGY, 2015, 22 : 118 - 118
  • [10] Effect of intramuscular interferon beta-1a on gray matter atrophy in relapsing-remitting multiple sclerosis: A retrospective analysis
    Fisher, E.
    Nakamura, K.
    Lee, J-C
    You, X.
    Sperling, B.
    Rudick, R. A.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 (05) : 668 - 676
12345